Skip to Content
Merck
CN

SML3560

MU380

≥98% (HPLC)

Synonym(s):

(R)-6-bromo-5-(piperidin-3-yl)-3-(1-(trifluoromethyl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-7-amine; 6-Bromo-5-(3R)-3-piperidinyl-3-[1-(trifluoromethyl)-1H-pyrazol-4-yl]-pyrazolo[1,5-a]pyrimidin-7-amine

Sign In to View Organizational & Contract Pricing.

Select a Size


About This Item

Empirical Formula (Hill Notation):
C15H15BrF3N7
CAS Number:
Molecular Weight:
430.23
UNSPSC Code:
12352200
NACRES:
NA.21
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

SMILES string

NC1=C(C([C@@]2([H])CNCCC2)=NC3=C(C=NN13)C4=CN(N=C4)C(F)(F)F)Br

assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

2-8°C

Quality Level

Biochem/physiol Actions

MU380 is a metabolically stable analog of CHK1 inhibitor SCH900776 (MK8776) does not undergo in vivo N-dealkylation. MU380 is a potent and selective CHK1 inhibitor, which potently sensitizes multiple cancer cell lines to DNA antimetabolites including hydroxyurea, cytarabine and gemcitabine.
Metabolically stable, potent and selective CHK1 inhibitor

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable


Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Novel CHK1 inhibitor MU380 exhibits significant single-agent activity in TP53-mutated chronic lymphocytic leukemia cells
Haematologica, 104, 2443-2455 (2019)
The CHK1 inhibitor MU380 significantly increases the sensitivity of human docetaxel-resistant prostate cancer cells to gemcitabine through the induction of mitotic catastrophe
Molecular Oncology, 14, 2487-2503 (2020)
Synthesis and Profiling of a Novel Potent Selective Inhibitor of CHK1 Kinase Possessing Unusual N-trifluoromethylpyrazole Pharmacophore Resistant to Metabolic N-dealkylation
Pounami Samadder, Fedor Nikulenkov, Hana Kolarova
Molecular Cancer Therapeutics, 16, 1831-1842 (2017)

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service